Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ.

Haematologica. 2018 Apr;103(4):655-665. doi: 10.3324/haematol.2017.178384. Epub 2018 Jan 19.

2.

Mesoscale Nanoparticles: An Unexpected Means for Selective Therapeutic Targeting of Kidney Diseases!

Yap ML, Wang X, Pietersz GA, Peter K.

Hypertension. 2018 Jan;71(1):61-63. doi: 10.1161/HYPERTENSIONAHA.117.09944. Epub 2017 Nov 13. No abstract available.

PMID:
29133359
3.

Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging.

Yap ML, McFadyen JD, Wang X, Zia NA, Hohmann JD, Ziegler M, Yao Y, Pham A, Harris M, Donnelly PS, Hogarth PM, Pietersz GA, Lim B, Peter K.

Theranostics. 2017 Jun 25;7(10):2565-2574. doi: 10.7150/thno.19900. eCollection 2017.

4.

Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies.

Pietersz GA, Wang X, Yap ML, Lim B, Peter K.

Nanomedicine (Lond). 2017 Aug;12(15):1873-1889. doi: 10.2217/nnm-2017-0043. Epub 2017 Jul 13. Review.

5.

Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides.

Brooks N, Esparon S, Pouniotis D, Pietersz GA.

Molecules. 2015 Aug 3;20(8):14033-50. doi: 10.3390/molecules200814033.

6.

Dendritic cell immunotherapy: clinical outcomes.

Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Stojanovska L, McKenzie IF, Vassilaros S.

Clin Transl Immunology. 2014 Jul 18;3(7):e21. doi: 10.1038/cti.2014.14. eCollection 2014 Jul. Review.

7.

Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses.

Trist HM, Tan PS, Wines BD, Ramsland PA, Orlowski E, Stubbs J, Gardiner EE, Pietersz GA, Kent SJ, Stratov I, Burton DR, Hogarth PM.

J Immunol. 2014 Jan 15;192(2):792-803. doi: 10.4049/jimmunol.1301554. Epub 2013 Dec 16.

8.

Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.

Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz GA, McKenzie IF, Apostolopoulos V.

Immunotherapy. 2013 Nov;5(11):1177-82. doi: 10.2217/imt.13.126.

PMID:
24188672
9.

Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration.

Gartlan KH, Wee JL, Demaria MC, Nastovska R, Chang TM, Jones EL, Apostolopoulos V, Pietersz GA, Hickey MJ, van Spriel AB, Wright MD.

Eur J Immunol. 2013 May;43(5):1208-19. doi: 10.1002/eji.201242730. Epub 2013 Mar 25.

10.

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Hogarth PM, Pietersz GA.

Nat Rev Drug Discov. 2012 Mar 30;11(4):311-31. doi: 10.1038/nrd2909. Review.

PMID:
22460124
11.

Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.

Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA.

Immunol Cell Biol. 2011 Nov;89(8):904-13. doi: 10.1038/icb.2011.13. Epub 2011 Mar 8.

PMID:
21383765
12.

A membrane penetrating multiple antigen peptide (MAP) incorporating ovalbumin CD8 epitope induces potent immune responses in mice.

Brooks NA, Pouniotis DS, Sheng KC, Apostolopoulos V, Pietersz GA.

Biochim Biophys Acta. 2010 Dec;1798(12):2286-95. doi: 10.1016/j.bbamem.2010.05.007. Epub 2010 May 15.

13.

Reactive oxygen species level defines two functionally distinctive stages of inflammatory dendritic cell development from mouse bone marrow.

Sheng KC, Pietersz GA, Tang CK, Ramsland PA, Apostolopoulos V.

J Immunol. 2010 Mar 15;184(6):2863-72. doi: 10.4049/jimmunol.0903458. Epub 2010 Feb 22.

14.

Cell-penetrating peptides: application in vaccine delivery.

Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA.

Biochim Biophys Acta. 2010 Jan;1805(1):25-34. doi: 10.1016/j.bbcan.2009.09.004. Epub 2009 Sep 25. Review.

PMID:
19782720
15.

Intracellular detection and immune signaling pathways of DNA vaccines.

Tang CK, Pietersz GA.

Expert Rev Vaccines. 2009 Sep;8(9):1161-70. doi: 10.1586/erv.09.79. Review.

PMID:
19722890
16.

Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier.

Tang CK, Sheng KC, Esparon SE, Proudfoot O, Apostolopoulos V, Pietersz GA.

Biomaterials. 2009 Mar;30(7):1389-400. doi: 10.1016/j.biomaterials.2008.11.010. Epub 2008 Dec 6.

PMID:
19058846
17.

Inhibition of destructive autoimmune arthritis in FcgammaRIIa transgenic mice by small chemical entities.

Pietersz GA, Mottram PL, van de Velde NC, Sardjono CT, Esparon S, Ramsland PA, Moloney G, Baell JB, McCarthy TD, Matthews BR, Powell MS, Hogarth PM.

Immunol Cell Biol. 2009 Jan;87(1):3-12. doi: 10.1038/icb.2008.82. Epub 2008 Nov 25.

PMID:
19030019
18.

Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors.

Tang CK, Sheng KC, Apostolopoulos V, Pietersz GA.

Expert Rev Vaccines. 2008 Sep;7(7):1005-18. doi: 10.1586/14760584.7.7.1005. Review.

PMID:
18767950
19.

The adjuvanticity of a mannosylated antigen reveals TLR4 functionality essential for subset specialization and functional maturation of mouse dendritic cells.

Sheng KC, Kalkanidis M, Pouniotis DS, Wright MD, Pietersz GA, Apostolopoulos V.

J Immunol. 2008 Aug 15;181(4):2455-64.

20.

Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses.

Tang CK, Sheng KC, Pouniotis D, Esparon S, Son HY, Kim CW, Pietersz GA, Apostolopoulos V.

Vaccine. 2008 Jul 23;26(31):3827-34. doi: 10.1016/j.vaccine.2008.05.008. Epub 2008 May 22.

PMID:
18550230
21.

Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo.

Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, Pietersz GA.

Eur J Immunol. 2008 Feb;38(2):424-36. doi: 10.1002/eji.200737578.

22.

An FcgammaRIIa-binding peptide that mimics the interaction between FcgammaRIIa and IgG.

Cendron AC, Wines BD, Brownlee RT, Ramsland PA, Pietersz GA, Hogarth PM.

Mol Immunol. 2008 Jan;45(2):307-19. Epub 2007 Jul 30.

PMID:
17673295
23.

Dendritic cell vaccination.

Proudfoot O, Pouniotis D, Sheng KC, Loveland BE, Pietersz GA.

Expert Rev Vaccines. 2007 Aug;6(4):617-33. Review.

PMID:
17669014
24.

Mannan-mediated gene delivery for cancer immunotherapy.

Tang CK, Lodding J, Minigo G, Pouniotis DS, Plebanski M, Scholzen A, McKenzie IF, Pietersz GA, Apostolopoulos V.

Immunology. 2007 Mar;120(3):325-35.

25.

Enhanced immune responses to an adenovirus CEA vaccine in CD4+CD25+ regulatory T-cell inactivated mice.

Pietersz GA.

Expert Rev Vaccines. 2007 Feb;6(1):21-3. No abstract available.

PMID:
17280474
26.

Receptor-mediated delivery of antigens to dendritic cells: anticancer applications.

Proudfoot O, Apostolopoulos V, Pietersz GA.

Mol Pharm. 2007 Jan-Feb;4(1):58-72. Epub 2007 Jan 17. Review.

PMID:
17228857
27.

Structure and design of polycationic carriers for gene delivery.

Pietersz GA, Tang CK, Apostolopoulos V.

Mini Rev Med Chem. 2006 Dec;6(12):1285-98. Review.

PMID:
17168805
28.

Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.

Lazoura E, Lodding J, Farrugia W, Ramsland PA, Stevens J, Wilson IA, Pietersz GA, Apostolopoulos V.

Immunology. 2006 Nov;119(3):306-16.

29.

Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy.

Minigo G, Scholzen A, Tang CK, Hanley JC, Kalkanidis M, Pietersz GA, Apostolopoulos V, Plebanski M.

Vaccine. 2007 Jan 26;25(7):1316-27. Epub 2006 Oct 10.

PMID:
17052812
30.

Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity.

Kalkanidis M, Pietersz GA, Xiang SD, Mottram PL, Crimeen-Irwin B, Ardipradja K, Plebanski M.

Methods. 2006 Sep;40(1):20-9.

PMID:
16997710
31.

Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells.

Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V.

Immunology. 2006 Jul;118(3):372-83.

32.

Design of peptide-based vaccines for cancer.

Pietersz GA, Pouniotis DS, Apostolopoulos V.

Curr Med Chem. 2006;13(14):1591-607. Review.

PMID:
16787206
33.

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, Piddlesden SJ, Plebanski M, Pouniotis DS, Alexis MN, McKenzie IF, Vassilaros S.

Breast Cancer Res. 2006;8(3):R27. Epub 2006 Jun 15.

34.

Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses.

Apostolopoulos V, Pouniotis DS, van Maanen PJ, Andriessen RW, Lodding J, Xing PX, McKenzie IF, Loveland BE, Pietersz GA.

Vaccine. 2006 Apr 12;24(16):3191-202. Epub 2006 Jan 25.

PMID:
16480791
35.
36.

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77.

37.

Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker.

Tselios TV, Lamari FN, Karathanasopoulou I, Katsara M, Apostolopoulos V, Pietersz GA, Matsoukas JM, Karamanos NK.

Anal Biochem. 2005 Dec 1;347(1):121-8. Epub 2005 Oct 3.

PMID:
16246290
38.

Dendritic cells: activation and maturation--applications for cancer immunotherapy.

Sheng KC, Pietersz GA, Wright MD, Apostolopoulos V.

Curr Med Chem. 2005;12(15):1783-800. Review.

PMID:
16029147
39.

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IF, Plebanski M.

J Immunol. 2004 Sep 1;173(5):3148-54.

40.

Cripto: a novel target for antibody-based cancer immunotherapy.

Xing PX, Hu XF, Pietersz GA, Hosick HL, McKenzie IF.

Cancer Res. 2004 Jun 1;64(11):4018-23.

41.

Aspects of cancer immunotherapy.

McKenzie IF, Apostolopoulos V, Plebanski M, Pietersz GA, Loveland BE.

Immunol Cell Biol. 2003 Feb;81(1):79-85.

PMID:
12534951
42.

Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design.

Apostolopoulos V, Yu M, Corper AL, Teyton L, Pietersz GA, McKenzie IF, Wilson IA, Plebanski M.

J Mol Biol. 2002 May 17;318(5):1293-305. Erratum in: J Mol Biol 2002 Sep 13;322(2):477.

PMID:
12083518
43.

LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival.

Pietersz GA, Sandrin MS, Ling S, Li YQ, McKenzie IFC.

Transpl Immunol. 2001 Oct;9(1):7-11.

PMID:
11680574
44.

MUC1 and breast cancer.

Apostolopoulos V, Pietersz GA, McKenzie IF.

Curr Opin Mol Ther. 1999 Feb;1(1):98-103. Review.

PMID:
11249691
45.

A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway.

Pietersz GA, Li W, Apostolopoulos V.

Vaccine. 2001 Jan 8;19(11-12):1397-405.

PMID:
11163662
46.

Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway.

Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF.

Eur J Immunol. 2000 Jun;30(6):1714-23.

47.

The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan.

Vaughan HA, Ho DW, Karanikas V, Sandrin MS, McKenzie IF, Pietersz GA.

Vaccine. 2000 Aug 1;18(28):3297-309.

PMID:
10869775
48.

Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses.

Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF.

Vaccine. 2000 Jul 15;18(27):3174-84.

PMID:
10856797
49.

Generation of MUC1 cytotoxic T-cells in mice and epitope mapping.

Apostolopoulos V, McKenzie IF, Pietersz GA.

Methods Mol Biol. 2000;125:455-62. Review. No abstract available.

PMID:
10820781
50.

Generation of cellular immune responses to antigenic tumor peptides.

Pietersz GA, Apostolopoulos V, McKenzie IF.

Cell Mol Life Sci. 2000 Feb;57(2):290-310. Review.

PMID:
10766024

Supplemental Content

Loading ...
Support Center